Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29252918 | 1.00 | ALDH1A1 (0.42) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| Hydrochloric Acid SCHEMBL27371328 | 1.00 | ALDH1A1 (0.42) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| Hydrochloric Acid SCHEMBL16774421 | 1.00 | ALDH1A1 (0.42) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| SCHEMBL27485167 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| SCHEMBL21416476 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| SCHEMBL24919973 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| SCHEMBL19223903 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| Hydrochloric Acid SCHEMBL2207969 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| SCHEMBL28143791 | 0.98 | MAPT (0.44) | ALDH1A1POLBMAPTNAAASLC2A1 | |
| Fluoride SCHEMBL29252743 | 0.96 | MAPT (0.42) | ALDH1A1POLBMAPTNAAASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081673-A1 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | THE PROCTER & GAMBLE COMPANY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2019023453-A1 | HALOGEN COMPLEXES OF COMPOUNDS COMPRISING AT LEAST ONE ETHER, THIOETHER, AND/OR IMINE MOIETY AND AT LEAST TWO LACTAM MOIETIES | ISP INVESTMENTS LLC (US) | 2019-01-31 | — | — | WO | disclosed |
| CN-109069363-A | Oral care compositions comprising a gel network and potassium nitrate | 宝洁公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108430436-A | Include the oral care composition of at least one phosphate/acrylate copolymer and at least one cationic active constituent | 高露洁-棕榄公司 | 2018-08-21 | — | — | CN | disclosed |
| EP-3331615-A1 | PERSONAL CARE COMPOSITIONS COMPRISING POLYMERS DERIVED FROM VINYL ALCOHOL ETHERS AND APPLICATIONS THEREOF | ISP Investments LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331491-A1 | POLYMERS DERIVED FROM AMINO-FUNCTIONAL VINYL ALCOHOL ETHERS AND APPLICATIONS THEREOF | ISP Investments LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| CN-107106498-A | Method for producing a drug delivery system | 欧米亚国际集团 | 2017-08-29 | — | — | CN | disclosed |
| WO-2017024110-A1 | POLYMERS DERIVED FROM AMINO-FUNCTIONAL VINYL ALCOHOL ETHERS AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024016-A1 | PERSONAL CARE COMPOSITIONS COMPRISING POLYMERS DERIVED FROM VINYL ALCOHOL ETHERS AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-3126417-A1 | VINYL LACTAM-DERIVED POLYMERS, COMPOSITIONS THEREOF HAVING ENHANCED WATER-RESISTANCE, AND METHODS OF USE THEREOF | ISP Investments Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2007117498-A2 | ORAL CARE REGIMENS AND KITS | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007041548-A2 | COMPOSITION FOR REGULATION OF MAMMALIAN KERATINOUS TISSUE | THE PROCTER & GAMBLE COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| CN-1894286-A | Redox polymerization method, water-absorbent resin composite, and absorbent article | MITSUBISHI CHEM CORP (JP) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006124990-A2 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1708791-A1 | ORAL CARE COMPOSITIONS COMPRISING INCREASED BIOAVAILABLE LEVELS OF QUATERNARY AMMONIUM ANTIMICROBIALS | The Procter and Gamble Company (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005072693-A1 | ORAL CARE COMPOSITIONS COMPRISING INCREASED BIOAVAILABLE LEVELS OF QUATERNARY AMMONIUM ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2001082922-A1 | ORAL COMPOSITIONS COMPRISING POLYPHENOL HERBAL EXTRACTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1085852-A1 | CLEAR DENTRIFRICE GELS | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001017494-A1 | ORAL COMPOSITIONS COMPRISING TEA POLYPHENOL | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-1999063960-A1 | CLEAR DENTRIFRICE GELS | THE PROCTER & GAMBLE COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |